The migration pattern for Americans continues to be toward the West and the South, according to the results of the latest United Van Lines annual national movers study. The pace of those moving to…
Strong sales of both the Jeep and Ram brands pushed Fiat Chrysler's December sales up by 14% year over year and up 9% for the full year.
Ford reported December and full-year 2018 sales Thursday morning that were both lower than last December and 2017. Passenger car sales were down more than 18% for the full year and nearly 28% in…
Sesen Bio shares took a beating on Thursday despite posting positive data for its late-stage trial for patients with high-grade non-muscle invasive bladder cancer.
Manufacturing activity is slowing. That’s the view of the Institute for Supply Management’s Report on Business for the month of December. The Purchasing Managers Index came in at 54.1%. While this still represents growth…
GM reported fourth-quarter and full-year sales Thursday morning that were weaker than sales in the year-ago quarter and all of 2017. Passenger car sales continue to tumble and light truck sales were not much…
The ADP National Employment Report showed that its sampling pool of companies added a sharp 271,000 private sector jobs during the month of December.
Even though 2018 was in many respects a a strong year for the economy, job cut announcements were up 28% compared to 2017. According to a January release by executive outplacement firm Challenger, Gray…
DBV Technologies shares made a handy gain on Thursday after the company announced that it would be making some changes in its senior leadership ahead of its anticipated resubmission of its Viaskin Peanut Biologics…
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators and Teva Pharmaceutical.
Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene shareholders are scheduled to receive a 54% premium to Wednesday night's closing stock price.
Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series of approvals in Japan.
Price target cuts across the board, ratings mostly unchanged.
Announced job cuts for 2018 reached their highest level since 2015 and the second-highest total since 2011. Announced hiring plans were lower year over year.
Applications for new mortgages fell by nearly 10% in the final two weeks of December, according to the Mortgage Bankers Association. Mortgage loan rates have moderated on most types of loans, though.
